TY  - JOUR
AU  - Fuchs, Anke
AU  - Gliwiński, Mateusz
AU  - Grageda, Nathali
AU  - Spiering, Rachel
AU  - Abbas, Abul K.
AU  - Appel, Silke
AU  - Bacchetta, Rosa
AU  - Battaglia, Manuela
AU  - Berglund, David
AU  - Blazar, Bruce
AU  - Bluestone, Jeffrey A.
AU  - Bornhäuser, Martin
AU  - Ten Brinke, Anja
AU  - Brusko, Todd M.
AU  - Cools, Nathalie
AU  - Cuturi, Maria Cristina
AU  - Geissler, Edward
AU  - Giannoukakis, Nick
AU  - Gołab, Karolina
AU  - Hafler, David A.
AU  - van Ham, S. Marieke
AU  - Hester, Joanna
AU  - Hippen, Keli
AU  - Di Ianni, Mauro
AU  - Radulović, Nataša
AU  - Isaacs, John
AU  - Issa, Fadi
AU  - Iwaszkiewicz-Grześ, Dorota
AU  - Jaeckel, Elmar
AU  - Joosten, Irma
AU  - Klatzmann, David
AU  - Koenen, Hans
AU  - van Kooten, Cees
AU  - Korsgren, Olle
AU  - Kretschmer, Karsten
AU  - Levings, Megan
AU  - Marek-Trzonkowska, Natalia Maria
AU  - Martinez-Llordella, Marc
AU  - Miljković, Đorđe
AU  - Mills, Kingston H G
AU  - Miranda, Joana P.
AU  - Piccirillo, Ciriaco A.
AU  - Putnam, Amy L.
AU  - Ritter, Thomas
AU  - Roncarolo, Maria Grazia
AU  - Sakaguchi, Shimon
AU  - Sánchez-Ramón, Silvia
AU  - Sawitzki, Birgit
AU  - Sofronic-Milosavljevic, Ljiljana
AU  - Sykes, Megan
AU  - Tang, Qizhi
AU  - Vives-Pi, Marta
AU  - Waldmann, Herman
AU  - Witkowski, Piotr
AU  - Wood, Kathryn J.
AU  - Gregori, Silvia
AU  - Hilkens, Catharien M. U.
AU  - Lombardi, Giovanna
AU  - Lord, Phillip
AU  - Martinez-Caceres, Eva M.
AU  - Trzonkowski, Piotr
PY  - 2018
UR  - http://journal.frontiersin.org/article/10.3389/fimmu.2017.01844/full
UR  - http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5775516
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3539
AB  - Cellular therapies with CD4+ T regulatory cells (Tregs) hold promise of efficacious treatment for the variety of autoimmune and allergic diseases as well as posttransplant complications. Nevertheless, current manufacturing of Tregs as a cellular medicinal product varies between different laboratories, which in turn hampers precise comparisons of the results between the studies performed. While the number of clinical trials testing Tregs is already substantial, it seems to be crucial to provide some standardized characteristics of Treg products in order to minimize the problem. We have previously developed reporting guidelines called minimum information about tolerogenic antigen-presenting cells, which allows the comparison between different preparations of tolerance-inducing antigen-presenting cells. Having this experience, here we describe another minimum information about Tregs (MITREG). It is important to note that MITREG does not dictate how investigators should generate or characterize Tregs, but it does require investigators to report their Treg data in a consistent and transparent manner. We hope this will, therefore, be a useful tool facilitating standardized reporting on the manufacturing of Tregs, either for research purposes or for clinical application. This way MITREG might also be an important step toward more standardized and reproducible testing of the Tregs preparations in clinical applications.
T2  - Frontiers in Immunology
T1  - Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization.
VL  - 8
DO  - 10.3389/fimmu.2017.01844
SP  - 1844
ER  - 

@article{
author = "Fuchs, Anke and Gliwiński, Mateusz and Grageda, Nathali and Spiering, Rachel and Abbas, Abul K. and Appel, Silke and Bacchetta, Rosa and Battaglia, Manuela and Berglund, David and Blazar, Bruce and Bluestone, Jeffrey A. and Bornhäuser, Martin and Ten Brinke, Anja and Brusko, Todd M. and Cools, Nathalie and Cuturi, Maria Cristina and Geissler, Edward and Giannoukakis, Nick and Gołab, Karolina and Hafler, David A. and van Ham, S. Marieke and Hester, Joanna and Hippen, Keli and Di Ianni, Mauro and Radulović, Nataša and Isaacs, John and Issa, Fadi and Iwaszkiewicz-Grześ, Dorota and Jaeckel, Elmar and Joosten, Irma and Klatzmann, David and Koenen, Hans and van Kooten, Cees and Korsgren, Olle and Kretschmer, Karsten and Levings, Megan and Marek-Trzonkowska, Natalia Maria and Martinez-Llordella, Marc and Miljković, Đorđe and Mills, Kingston H G and Miranda, Joana P. and Piccirillo, Ciriaco A. and Putnam, Amy L. and Ritter, Thomas and Roncarolo, Maria Grazia and Sakaguchi, Shimon and Sánchez-Ramón, Silvia and Sawitzki, Birgit and Sofronic-Milosavljevic, Ljiljana and Sykes, Megan and Tang, Qizhi and Vives-Pi, Marta and Waldmann, Herman and Witkowski, Piotr and Wood, Kathryn J. and Gregori, Silvia and Hilkens, Catharien M. U. and Lombardi, Giovanna and Lord, Phillip and Martinez-Caceres, Eva M. and Trzonkowski, Piotr",
year = "2018",
abstract = "Cellular therapies with CD4+ T regulatory cells (Tregs) hold promise of efficacious treatment for the variety of autoimmune and allergic diseases as well as posttransplant complications. Nevertheless, current manufacturing of Tregs as a cellular medicinal product varies between different laboratories, which in turn hampers precise comparisons of the results between the studies performed. While the number of clinical trials testing Tregs is already substantial, it seems to be crucial to provide some standardized characteristics of Treg products in order to minimize the problem. We have previously developed reporting guidelines called minimum information about tolerogenic antigen-presenting cells, which allows the comparison between different preparations of tolerance-inducing antigen-presenting cells. Having this experience, here we describe another minimum information about Tregs (MITREG). It is important to note that MITREG does not dictate how investigators should generate or characterize Tregs, but it does require investigators to report their Treg data in a consistent and transparent manner. We hope this will, therefore, be a useful tool facilitating standardized reporting on the manufacturing of Tregs, either for research purposes or for clinical application. This way MITREG might also be an important step toward more standardized and reproducible testing of the Tregs preparations in clinical applications.",
journal = "Frontiers in Immunology",
title = "Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization.",
volume = "8",
doi = "10.3389/fimmu.2017.01844",
pages = "1844"
}

Fuchs, A., Gliwiński, M., Grageda, N., Spiering, R., Abbas, A. K., Appel, S., Bacchetta, R., Battaglia, M., Berglund, D., Blazar, B., Bluestone, J. A., Bornhäuser, M., Ten Brinke, A., Brusko, T. M., Cools, N., Cuturi, M. C., Geissler, E., Giannoukakis, N., Gołab, K., Hafler, D. A., van Ham, S. M., Hester, J., Hippen, K., Di Ianni, M., Radulović, N., Isaacs, J., Issa, F., Iwaszkiewicz-Grześ, D., Jaeckel, E., Joosten, I., Klatzmann, D., Koenen, H., van Kooten, C., Korsgren, O., Kretschmer, K., Levings, M., Marek-Trzonkowska, N. M., Martinez-Llordella, M., Miljković, Đ., Mills, K. H. G., Miranda, J. P., Piccirillo, C. A., Putnam, A. L., Ritter, T., Roncarolo, M. G., Sakaguchi, S., Sánchez-Ramón, S., Sawitzki, B., Sofronic-Milosavljevic, L., Sykes, M., Tang, Q., Vives-Pi, M., Waldmann, H., Witkowski, P., Wood, K. J., Gregori, S., Hilkens, C. M. U., Lombardi, G., Lord, P., Martinez-Caceres, E. M.,& Trzonkowski, P.. (2018). Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization.. in Frontiers in Immunology, 8, 1844.
https://doi.org/10.3389/fimmu.2017.01844

Fuchs A, Gliwiński M, Grageda N, Spiering R, Abbas AK, Appel S, Bacchetta R, Battaglia M, Berglund D, Blazar B, Bluestone JA, Bornhäuser M, Ten Brinke A, Brusko TM, Cools N, Cuturi MC, Geissler E, Giannoukakis N, Gołab K, Hafler DA, van Ham SM, Hester J, Hippen K, Di Ianni M, Radulović N, Isaacs J, Issa F, Iwaszkiewicz-Grześ D, Jaeckel E, Joosten I, Klatzmann D, Koenen H, van Kooten C, Korsgren O, Kretschmer K, Levings M, Marek-Trzonkowska NM, Martinez-Llordella M, Miljković Đ, Mills KHG, Miranda JP, Piccirillo CA, Putnam AL, Ritter T, Roncarolo MG, Sakaguchi S, Sánchez-Ramón S, Sawitzki B, Sofronic-Milosavljevic L, Sykes M, Tang Q, Vives-Pi M, Waldmann H, Witkowski P, Wood KJ, Gregori S, Hilkens CMU, Lombardi G, Lord P, Martinez-Caceres EM, Trzonkowski P. Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization.. in Frontiers in Immunology. 2018;8:1844.
doi:10.3389/fimmu.2017.01844 .

Fuchs, Anke, Gliwiński, Mateusz, Grageda, Nathali, Spiering, Rachel, Abbas, Abul K., Appel, Silke, Bacchetta, Rosa, Battaglia, Manuela, Berglund, David, Blazar, Bruce, Bluestone, Jeffrey A., Bornhäuser, Martin, Ten Brinke, Anja, Brusko, Todd M., Cools, Nathalie, Cuturi, Maria Cristina, Geissler, Edward, Giannoukakis, Nick, Gołab, Karolina, Hafler, David A., van Ham, S. Marieke, Hester, Joanna, Hippen, Keli, Di Ianni, Mauro, Radulović, Nataša, Isaacs, John, Issa, Fadi, Iwaszkiewicz-Grześ, Dorota, Jaeckel, Elmar, Joosten, Irma, Klatzmann, David, Koenen, Hans, van Kooten, Cees, Korsgren, Olle, Kretschmer, Karsten, Levings, Megan, Marek-Trzonkowska, Natalia Maria, Martinez-Llordella, Marc, Miljković, Đorđe, Mills, Kingston H G, Miranda, Joana P., Piccirillo, Ciriaco A., Putnam, Amy L., Ritter, Thomas, Roncarolo, Maria Grazia, Sakaguchi, Shimon, Sánchez-Ramón, Silvia, Sawitzki, Birgit, Sofronic-Milosavljevic, Ljiljana, Sykes, Megan, Tang, Qizhi, Vives-Pi, Marta, Waldmann, Herman, Witkowski, Piotr, Wood, Kathryn J., Gregori, Silvia, Hilkens, Catharien M. U., Lombardi, Giovanna, Lord, Phillip, Martinez-Caceres, Eva M., Trzonkowski, Piotr, "Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization." in Frontiers in Immunology, 8 (2018):1844,
https://doi.org/10.3389/fimmu.2017.01844 . .

TY  - JOUR
AU  - Stojanović, Ivana D.
AU  - Dimitrijević, Mirjana
AU  - Vives-Pi, Marta
AU  - Mansilla, Maria Jose
AU  - Pujol-Autonell, Irma
AU  - Rodríguez-Fernandez, Silvia
AU  - Palova-Jelínkova, Lenka
AU  - Funda, David P.
AU  - Gruden-Movsesijan, Alisa
AU  - Sofronić-Milosavljević, Ljiljana
AU  - Hilkens, Catharien M. U.
AU  - Caceres, Eva Martinez
AU  - Miljković, Đorđe
PY  - 2017
UR  - http://www.eurekaselect.com/150098/article
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2819
AB  - Cell-based tolerogenic therapy is a promising approach for the treatment of autoimmune diseases and transplant rejection. Regulatory T cells and tolerogenic dendritic cells have been particularly explored in the treatment of various autoimmune disorders in experimental models of disease. Although some of these cells have already been tested in a limited number of clinical trials, there is still a need for preclinical research on tolerogenic cells in animal models of autoimmunity. This review will focus on the relevance of data obtained from studies in experimental animal models for the use of tolerogenic cell-based therapy in humans. Also, perspectives for further improvement of tolerogenic cell preparation towards enhanced suppressive activity and stability of the cells will be discussed.
T2  - Current Pharmaceutical Design
T1  - Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis
IS  - 18
VL  - 23
DO  - 10.2174/1381612823666170214120708
SP  - 2623
EP  - 2643
ER  - 

@article{
author = "Stojanović, Ivana D. and Dimitrijević, Mirjana and Vives-Pi, Marta and Mansilla, Maria Jose and Pujol-Autonell, Irma and Rodríguez-Fernandez, Silvia and Palova-Jelínkova, Lenka and Funda, David P. and Gruden-Movsesijan, Alisa and Sofronić-Milosavljević, Ljiljana and Hilkens, Catharien M. U. and Caceres, Eva Martinez and Miljković, Đorđe",
year = "2017",
abstract = "Cell-based tolerogenic therapy is a promising approach for the treatment of autoimmune diseases and transplant rejection. Regulatory T cells and tolerogenic dendritic cells have been particularly explored in the treatment of various autoimmune disorders in experimental models of disease. Although some of these cells have already been tested in a limited number of clinical trials, there is still a need for preclinical research on tolerogenic cells in animal models of autoimmunity. This review will focus on the relevance of data obtained from studies in experimental animal models for the use of tolerogenic cell-based therapy in humans. Also, perspectives for further improvement of tolerogenic cell preparation towards enhanced suppressive activity and stability of the cells will be discussed.",
journal = "Current Pharmaceutical Design",
title = "Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis",
number = "18",
volume = "23",
doi = "10.2174/1381612823666170214120708",
pages = "2623-2643"
}

Stojanović, I. D., Dimitrijević, M., Vives-Pi, M., Mansilla, M. J., Pujol-Autonell, I., Rodríguez-Fernandez, S., Palova-Jelínkova, L., Funda, D. P., Gruden-Movsesijan, A., Sofronić-Milosavljević, L., Hilkens, C. M. U., Caceres, E. M.,& Miljković, Đ.. (2017). Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis. in Current Pharmaceutical Design, 23(18), 2623-2643.
https://doi.org/10.2174/1381612823666170214120708

Stojanović ID, Dimitrijević M, Vives-Pi M, Mansilla MJ, Pujol-Autonell I, Rodríguez-Fernandez S, Palova-Jelínkova L, Funda DP, Gruden-Movsesijan A, Sofronić-Milosavljević L, Hilkens CMU, Caceres EM, Miljković Đ. Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis. in Current Pharmaceutical Design. 2017;23(18):2623-2643.
doi:10.2174/1381612823666170214120708 .

Stojanović, Ivana D., Dimitrijević, Mirjana, Vives-Pi, Marta, Mansilla, Maria Jose, Pujol-Autonell, Irma, Rodríguez-Fernandez, Silvia, Palova-Jelínkova, Lenka, Funda, David P., Gruden-Movsesijan, Alisa, Sofronić-Milosavljević, Ljiljana, Hilkens, Catharien M. U., Caceres, Eva Martinez, Miljković, Đorđe, "Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis" in Current Pharmaceutical Design, 23, no. 18 (2017):2623-2643,
https://doi.org/10.2174/1381612823666170214120708 . .